江晓霞,郝宇杰,蒲相宏,等.过继性细胞免疫治疗在卵巢癌中的研究进展[J].中国肿瘤,2025,34(6):491-497. |
过继性细胞免疫治疗在卵巢癌中的研究进展 |
Research Progress of Adoptive Cell Immunotherapy in Ovarian Cancer |
投稿时间:2025-02-10 |
DOI:10.11735/j.issn.1004-0242.2025.06.A010 |
|
 |
中文关键词: 过继性细胞免疫治疗 卵巢癌 临床研究进展 联合治疗策略 |
英文关键词:adoptive cell immunotherapy ovarian cancer clinical research advances combination therapy strategies |
基金项目:国家自然科学基金(82360533);云南省科技人才与平台计划(202405AF140059);云南省科技厅基础研究计划(202401AY070001-015) |
|
摘要点击次数: 43 |
全文下载次数: 15 |
中文摘要: |
摘 要:卵巢癌的死亡率居女性生殖道恶性肿瘤首位,又因其高复发率和对含铂化疗的继发性耐药,亟需开发新的有效治疗手段。近年来,过继性细胞免疫治疗(adoptive cell immunotherapy,ACT)作为一种新兴的免疫治疗策略,开始在卵巢癌的治疗中展现出巨大潜力。虽然免疫抑制微环境和靶点选择有限仍是当前卵巢癌ACT治疗面临的主要挑战,但通过优化细胞生产技术、联合多种治疗手段,仍有望进一步提高ACT在卵巢癌患者中的疗效。全文通过综述ACT治疗在卵巢癌中的作用机制及最新研究进展,旨在为卵巢癌创新疗法的开发提供参考。 |
英文摘要: |
Abstract: Ovarian cancer has the highest mortality rate in female malignant tumors of reproductive system, with high recurrence rate and secondary resistance to platinum-containing chemotherapy. In recent years, adoptive cell immunotherapy (ACT), as an emerging immunotherapeutic strategy, shows great potential in the treatment of ovarian cancer. Although the immunosuppressive microenvironment and limited target selection are still the main challenges facing the current ACT treatment for ovarian cancer, it is still expected that the efficacy of ACT in ovarian cancer patients can be further improved by optimizing the cell production techniques and combining multiple thera-peutic approaches. This paper aims to provide a reference for the development of innovative therapies for ovarian cancer by reviewing the latest research progress on the mechanism and application of ACT therapy in ovarian cancer. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |